NCT04472338 Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
| NCT ID | NCT04472338 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Washington |
| Condition | Prostate Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 450 participants |
| Start Date | 2020-05-21 |
| Primary Completion | 2030-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 450 participants in total. It began in 2020-05-21 with a primary completion date of 2030-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study investigates ways to detect prostate cancer earlier in people at genetic risk for disease that forms, grows, or spreads quickly (aggressive). Studying samples of blood, urine, and/or tissue in the laboratory may help doctors further understand the genetics of prostate cancer and help identify ways to detect cancer earlier, thereby improving treatment and methods of early detection in the future.
Eligibility Criteria
Inclusion Criteria: * People with prostates ≥40 years of age * Documented germline pathogenic variant in known or suspected genes associated with prostate cancer risk. Exclusion Criteria: * Prior diagnosis of prostate cancer * Medical contraindication to any of the study procedures (e.g., prostate biopsy) * For all cancer types except non-melanoma skin cancer, any cancer treatment with curative intent within the past 12 months (e.g., surgery, radiation, chemotherapy, immunotherapy) * Prior or concurrent participation in an interventional clinical trial aimed at preventing cancer for people with germline variants associated with increased prostate cancer risk * Unable to provide written informed consent * Unable or unwilling to complete clinical care and study procedures as indicated by the study protocol.
Contact & Investigator
Heather H. Cheng, MD, PhD
PRINCIPAL INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Frequently Asked Questions
Who can join the NCT04472338 clinical trial?
This trial is open to male participants only, aged 40 Years or older, studying Prostate Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04472338 currently recruiting?
Yes, NCT04472338 is actively recruiting participants. Contact the research team at patrol@uw.edu for enrollment information.
Where is the NCT04472338 trial being conducted?
This trial is being conducted at Duarte, United States, San Francisco, United States, Chicago, United States, Boston, United States and 4 additional locations.
Who is sponsoring the NCT04472338 clinical trial?
NCT04472338 is sponsored by University of Washington. The principal investigator is Heather H. Cheng, MD, PhD at Fred Hutch/University of Washington Cancer Consortium. The trial plans to enroll 450 participants.